LABP — Landos Biopharma Share News
0.000.00%
Last trade - 00:00Brief: Landos Biopharma To Collaborate On A Phase 2 Study Of Omilancor In Crohn’S Disease With The Icahn School Of Medicine
Landos to begin early-stage trial of autoimmune disease drug in Q4, shares up
Brief: Landos Biopharma Expects To Enter Phase 1 Trial Of Potential Lupus Treatment In Q4
Brief: Landos Biopharma Announces Research Collaboration Into NLRX1 Pathway In Multiple Sclerosis With Johns Hopkins University School Of Medicine
Landos Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Landos Biopharma Reports Q2 Results
Brief: Landos Biopharma's Phase 2 Data Of Omilancor In Ulcerative Colitis Accepted For Oral Presentation
Brief: Landos Biopharma Announces Positive Outcome Of End-Of-Phase 2 Meeting With The FDA
Brief: Landos Biopharma Announces The Appointment Of Tim M. Mayleben To Its Board Of Directors
Landos Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Landos Biopharma Inc QTRLY Loss Per Share $0.38
Brief: Landos Biopharma And LianBio Collaborate To Develop And Commercialize Omilancor And NX-13 In Greater China And Select Asian Markets
Brief: Landos Biopharma Inc - First Patient Dosed In A Phase 2 Study Of Omilancor For Moderate-To-Severe Crohn's Disease
Brief: Landos Biopharma To Present Two Late-Breaking Presentations On Therapeutic Potential Of Omilancor And Px-69 At The 2021 American Association Of Immunologists (Aai) Annual Meeting
U.S. STOCKS ON THE MOVE-Phunware Inc, Niu Technologies, Cara Therapeutics, gold miners
U.S. STOCKS ON THE MOVE-Ebang, Airbnb Inc, Scienjoy and Greenbrier Companies
U.S. STOCKS ON THE MOVE-Illumina, Crexendo Inc, Xcel Brands, Romeo Power
Landos Biopharma: Jumps as U.S. FDA clears esophageal disease study application
Brief: Landos Biopharma Inc - Landos Expects To Initiate Patient Dosing In First Half Of 2022